Signum Biosciences develops small molecule therapeutics derived from its STM platform to modulate signal transduction imbalances.
Industries BiotechnologyHealth CareLife ScienceTherapeuticsHeadquarters Regions Greater Denver Area, Western US Founded Date 2004 Founders Gregory Stock, Jeffry Stock, Maxwell Stock Operating Status Active Last Funding Type Grant
Company Type For Profit
Contact Email info@signumbio.com Phone Number 7323298344
Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from its Signal Transduction Modulation (STM) platform to modulate signal transduction imbalances. Through research on protein networks that control biological systems, Signum is developing therapeutic agents for several skin
conditions, Alzheimer's, Parkinson's, asthma and COPD. Signum's STM technology provides many opportunities for the development of novel consumer products and pharmaceutical candidates.